摘要
目的：观察转录因子（ NF）-κB在弥漫性大B细胞性淋巴瘤（ DLBCL）组织中的表达，并探讨其意义。方法采用免疫组化法检测82例DLBCL组织中的NF-κB，记录患者的临床资料和生存情况。结果 NF-κB阳性41例，生发中心B细胞样（GCB）型中NF-κB阳性率为23．53％，non-GCB型中为56．92％，P＜0．05。不同性别、年龄、部位、LDH水平、Ann Arbor分期、有无B症状的DLBCL患者NF-κB阳性率比较，P均＞0．05。随访76例，GCB型患者存活期为4～64个月，non-GCB型为0．5～41个月，P＜0．05。结论 non-GCB型DLBCL患者NF-κB阳性率在明显高于GCB型；NF-κB检测有助于判断DLBCL的临床亚型和预后。
Objective To investigate the expression and clinical significance of the transcription factors NF -kappa B （NF-κB） in large B cell lymphoma （DLBCL）.Methods The NF-κB expression in 82 DLBCL patients was detected by immunohistochemistry , and the clinical data and survival were recorded .Results The positive expression rates of NF-κB protein were 23.53%（41/82） in GCB-DLBCL and 56.92%in non-GCB （P〈0.05）.The NF-κB positive expression rate of DLBCL patients had no correlation with gender , age, position, LDH, Ann Arbor stages, B symptom and non-B symptom （all P〉0.05）.Seventy-six cases of patients were followed up .The median survival time of GCB and non-GCB was 4-64 months and 0.5-41 months, respectively （P〈0.05）.Conclusion The NF-κB positive expression rate in non-GCB DL-BCL patients is higher than that of GCB DLBCL patients , and the detection of NF-κB expression helps to determine the subtypes and prognosis of DLBCL .
出处
《山东医药》
CAS
2014年第16期16-18,I0002,共4页
Shandong Medical Journal
基金
杨森科学研究基金资助项目(JRCC2012肿瘤01)
